210 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Rank Status Study
21 Recruiting A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate
22 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib
23 Recruiting Pediatric Chronic Myeloid Leukemia Registry
Condition: Chronic Myeloid Leukemia
Intervention:
24 Unknown  Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Condition: Chronic Myeloid Leukemia
Interventions: Drug: mesylate imatinib capsule;   Drug: Glivec
25 Recruiting Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
26 Recruiting Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: Nilotinib
27 Recruiting De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Interventions: Drug: Imatinib;   Drug: nilotinib;   Drug: dasatinib
28 Not yet recruiting Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
29 Recruiting Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: PEG-IFN-a2b
30 Recruiting Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib stop
31 Recruiting Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Zileuton (Zyflo®)  Dasatinib (Sprycel®);   Drug: Dosing with Zileuton/Dasatinib in CML;   Drug: Daily dosing of Zileuton/Dasatinib;   Drug: Daily dosing with Zileuton/Dasatinib for CML
32 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
33 Recruiting Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Peginterferon α2b;   Drug: Nilotinib
34 Recruiting Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
35 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
36 Unknown  Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Conditions: Myelodysplastic Syndrome;   Myelofibrosis;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Luitpold Azacitidine;   Drug: Vidaza®
37 Recruiting Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)
Condition: Chronic Myeloid Leukemia or Ph Positive ALL
Intervention:
38 Recruiting Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
39 Recruiting Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Arsenic trioxide
40 Recruiting Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Condition: Chronic Myeloid Leukemia
Interventions: Behavioral: no access to eMedonline;   Behavioral: eMedonline access

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years